C
Chee Khoon Lee
Researcher at St George's Hospital
Publications - 141
Citations - 7372
Chee Khoon Lee is an academic researcher from St George's Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 27, co-authored 116 publications receiving 5392 citations. Previous affiliations of Chee Khoon Lee include National Health and Medical Research Council & Sutherland Hospital.
Papers
More filters
Journal ArticleDOI
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony Mok,Yi-Long Wu,Myung-Ju Ahn,Marina Chiara Garassino,Hye Ryoun Kim,Suresh S. Ramalingam,Frances A. Shepherd,Yong He,Hiroaki Akamatsu,Willemijn S. M. E. Theelen,Chee Khoon Lee,Martin Sebastian,A. Templeton,Helen Mann,Marcelo Marotti,Serban Ghiorghiu,Vassiliki A. Papadimitrakopoulou +16 more
TL;DR: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer as mentioned in this paper.
Journal ArticleDOI
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
Chee Khoon Lee,Chee Khoon Lee,Johnathan Man,Sarah J. Lord,Matthew Links,Val Gebski,Tony Mok,James Chih-Hsin Yang +7 more
TL;DR: In EGFR‐mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel, and Mechanisms of acquired resistance to first‐line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second‐line treatment for these patients.
Journal ArticleDOI
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee,Chris Brown,Richard J. Gralla,Vera Hirsh,Sumitra Thongprasert,Chun-Ming Tsai,Eng Huat Tan,James Chung-Man Ho,Da Tong Chu,Adel Zaatar,Jemela Anne Osorio Sanchez,Vu Van Vu,Joseph S. K. Au,Akira Inoue,Siow Ming Lee,Val Gebski,James Chih-Hsin Yang +16 more
TL;DR: EGFR mutation is a predictive biomarker of PFS benefit with EGFR-TKIs treatment in all settings and should be considered as front-line therapy in EGFRmut(+) advanced NSCLC patients, supporting EGFR mutation assessment before initiation of treatment.
Journal ArticleDOI
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Suresh S. Ramalingam,James Chih-Hsin Yang,Chee Khoon Lee,Takayasu Kurata,Dong Wan Kim,Thomas John,Naoyuki Nogami,Yuichiro Ohe,Helen Mann,Yuri Rukazenkov,Serban Ghiorghiu,Daniel Stetson,Aleksandra Markovets,J. Carl Barrett,Kenneth S. Thress,Pasi A. Jänne +15 more
TL;DR: Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC and there was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.
Journal ArticleDOI
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Chee Khoon Lee,Chee Khoon Lee,Johnathan Man,Sarah J. Lord,Wendy A Cooper,Wendy A Cooper,Matthew Links,Val Gebski,Roy S. Herbst,Richard J. Gralla,Richard J. Gralla,Tony Mok,James Chih-Hsin Yang +12 more
TL;DR: Checkpoint inhibitors, compared with docetaxel, are associated with significantly prolong overall survival in second-line therapy in NSCLC and should be considered only after other effective therapies have been exhausted.